- Florida-Grown Cucumbers Behind Salmonella Outbreak, CDC Warns
- Nebraska First State to Ban Soda, Energy Drinks From SNAP Program
- FDA Limits COVID-19 Boosters to Seniors, Other High-Risk Groups
- Deaths Waiting For Lung Donation Have Dropped Under New Guidelines
- Battling Multiple Chronic Illnesses Can Double Risk Of Depression
- 9 In 10 U.S. Teens Have Been Cyberbullied
- Blood, Urine Tests Can Identify Level Of Ultra-Processed Food In Diet
- Many Seniors Fear Cataract Surgery
- Bodybuilding Linked To Sudden Cardiac Deaths
- Possible Plastic Contamination Prompts Nationwide Ice Cream Recall
Northera Approved For Rare Blood Pressure Condition

Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.
Neurogenic orthostatic hypotension (NOH) is most often associated with Parkinson’s disease and other neurologic disorders. Symptoms may include dizziness, lightheadedness, blurred vision, fatigue and fainting, the FDA said in a news release.
Granted accelerated approval to treat a rare condition, the drug will have a boxed label warning that it could cause an unhealthy rise in blood pressure while a person is lying down. This potential side effect could lead to a stroke, the agency said, warning that Northera users should be monitored carefully.
Other less serious side effects could include headache, dizziness, nausea, high blood pressure and fatigue, the FDA said.
Northera is produced by Chelsea Therapeutics, based in Charlotte, N.C.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.